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Abstract
The study aim was to explore pharmacological effects of 2-aminoaethansulfonic acid compounds in reperfusion-in-
duced heart injury. 
Materials and methods. The study was performed on rats and dogs of both sexes, isolated rats’ hearts. Two compounds 
of 2-aminoethanesulfonic acid, magnesium-containing (LBK-527) and phenylacetamide-containing (LKhT-317) were 
investigated. Antiarrhythmic effects of the compounds were studied in coronary artery reperfusion 7, 30 and 120 min 
after acute myocardial ischemia modeling. The ability of the substances to limit the volume of reperfusion injury was 
investigated by differential indicator method. The influence of substances on the intensity of free radical processes in 
the myocardium, as well as the metabolic profile of coronary venous blood during reperfusion, was studied. Hemody-
namic effects of the substances were studied during in vivo experiments, as well as on an isolated heart. 
Results and discussion. The compounds effectively prevent cardiac arrhythmias generation caused by myocardi-
al reperfusion after 7, 30 and 120 minutes of ischemia. Prophylactic intravenous administration of LHT-317 and 
LBK-527 at higher therapeutic doses limit the size of rats’ heart necrosis zone after occlusion-reperfusion syndrome 
develops, prevent reperfusion-induced excessive activation of free-radical processes in rat myocardium, activate the 
antiradical activity of the heart tissues, and optimize [O2] and [CO2] in coronary venous sinus blood of dogs. Car-
dioprotective effect of the compounds manifests in preserving myocardium contractile function, maintaing BP and 
stabilizing heart chronotropic function.
Conclusions. The study analysis shows that 2-aminoethanesulfonic acid compounds have cardioprotective effect in 
reperfusion syndrome.
Keywords
ischemic and reperfusion heart injury, 2-aminoaethanesulfonic acid compounds, arrhythmia, hemodynamics, lipid ox-
idation, metabolic profile, isolated heart.
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Introduction
Acute occlusive and reperfusion-induced myocardial inju-
ry is the dominant cause of death of patients with coronary 
heart disease (Chin et al. 2015). Arising from the coronary 
artery recanalization, reperfusion syndrome is manifested 
by the development of cardiac arrhythmias, cardiomyo-
cytes death, and heart failure (Wit and Janse 2001). The 
most typical clinical situations that create the prerequisi-
tes for the development of reperfusion syndrome in car-
diology are acute myocardial infarction with ST-segment 
elevation on the ECG due, as a rule, to thrombosis at the 
site of atherosclerotic plaque rupture, interventional car-
diac surgeries, coronary artery bypass grafting and heart 
transplantation (Yellon and Hausenloy 2007).
Early reperfusion of ischemic myocardium seems to be 
a key event for maintaining the vital activity of myocardi-
al tissue and improving the clinical outcomes of an acute 
ischemic coronary disaster (Yellon and Hausenloy 2007). 
Paradoxically, as a result of the aforementioned reperfu-
sion strategy, subsequent deterioration of tissue, cellular 
and subcellular structures of the myocardium is more pro-
nounced than that observed only due to acute ischemia, 
with the formation of the so-called reperfusion syndrome.
It was first described in 1960 by Jennings, who ob-
served myocardial damage due to its reperfusion after a 
period of acute ischemia in dogs with swelling of cardiac 
cells, contracture of myofibrils and calcification of mi-
tochondria of cardiomyocytes. Later, it was proved that 
the reperfusion strategy induced death of the viable car-
diomyocytes in ischemic zone and increased the size of 
infarction (tissue death). Moreover, the authors found that 
at least 50% of the final dimensions of the necrosis area 
was due to the reperfusion injury of heart tissue. Thus, it 
was shown that pharmacological intervention during the 
reperfusion period aimed at preserving the vital activity of 
the ischemic myocardium seemed to be a realistic scenar-
io in terms of the possibility of limiting the size of organ 
damage (Karwi et al. 2018).
However, despite numerous experimental studies of 
various pharmacological approaches to the prevention and 
treatment of reperfusion syndrome, up to now there is no 
strategy with proven clinical efficacy (Chin et al. 2015).
Currently, it is believed that the key elements of reper-
fusion injury of internal organs are overproduction of re-
active oxygen intermediates, cell overloading with Ca2+, 
tissue inflammatory cells infiltration. In the myocardium, 
this leads to the formation of pharmacoresistant reperfu-
sion arrhythmias, stunning, microcirculatory dysfunction, 
hemodynamic disorders, and death of cardiomyocytes 
(Maxwell and Lip 1997).
Now numerous promising molecules of drugs are be-
ing studied with a high potency to have cardioprotective, 
antiischemic and antiarrhythmic properties, to correct en-
dothelial dysfunction in order to normalize regulation of 
vascular pressure and microcirculatory blood flow (Blino-
va et al. 2016, Vasilkina et al. 2016, Shakhno et al. 2018, 
Pokrovskii et al. 2017). Among the substances of the 
kinds, our attention was drawn to salts of 2-aminoethane-
sulfonic acid containing magnesium and dimethylpheny-
lacetamide as a base. These compounds were chosen to 
study the possibilities of preventive effects on the myo-
cardium with the purpose of developing a pharmacolog-
ical strategy to prevent reperfusion injury of the heart, 
which is a major challenge of pharmacology.
Materials and methods
All the study protocols were reviewed and approved of 
by the Local Ethics Committee of Ogarev Mordovia State 
University (Protocol No. 10 of October 21, 2015).
Animals and biological materials 
The study was carried out in 174 non-linear white rats of 
both sexes with the initial weight of 180-220 g, obtained 
from “Andreevka” Animal Husbandry Facility (Russia) and 
20 mongrel dogs of both sexes weighing 10.0-15.0 kg. The 
animals were maintained in a special facility of The Center 
for Advanced Studies of Innovative Medicines of Ogarev 
Mordovia State University under the conditions which met 
all the requirements of National Standard of the Russian 
Federation “Principles of Good Laboratory Practice”.
All the painful procedures and manipulations were per-
formed under general anesthesia. Barbiturate anesthesia 
(thiopental sodium intravenously/intrapleurally) or ethe-
real anesthesia (ether for anesthesia inhalation by using 
TOPO Small Animal Ventilator, Kent Scientific, USA) 
was used.
Substances and drugs
In the study, two original substances – chemical com-
pounds containing the residue of 2-aminoethanesulfonic 
acid, synthesized at the Department of Chemistry and 
Synthetic Drugs Technology of All-Union Research Cen-
ter for Safety of Biologically Active Substances (Russia) 
– were used. Figure 1 shows the chemical structures of 
the compounds: 2-(diethylamino)-N-(2,6-dimethylphe-
nyl)-acetamide 2-atsetaminoetansulfonoate (laboratory 
code LKhT-317) and Magnesium bis-acetaminoethane-
sulfonate (laboratory code LBK-527). LKhT-317 is white 
fine crystalline powder, highly soluble in water, odorless 
or with a slight smell of hydrogen sulfide. LBK-527 is 
white crystalline powder that is highly soluble in water, 
without smell.
At all stages of the study, in order to obtain objective 
results, reproducible experimental models and to identify 
the advantages, reference medications at isotoxic doses 
that were equivalent to those of the tested substances. Ref-
erence medications used were as follows: 1) Lidocaine 
hydrochloride (officinal liquid dosage form “Lidocaine”, 
injection solution, 20 mg/ml, 2 ml, ampouled, manufac-
tured by “Egis” (Hungary), series No. T111A1014, exp. 
date 10.2019); 2) Amiodarone (officinal liquid dosage 
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form “Kordaron”, solution for intravenous administra-
tion, 50 mg/ml, 3 ml, ampouled, manufactured by “Sanofi 
Aventis – FRANCE” (France), series No. 6A011, exp. 
date 01.2018); 3) Verapamil (officinal liquid dosage form 
“Verapamil”, solution for intravenous administration, 2.5 
mg/ml, 2 ml, ampouled, manufactured by “Alkaloid AO” 
(Republic of Macedonia)), lot 0716 No 98836, exp. date 
07.2019); 4) Propranolol (officinal liquid dosage form 
“Obzidan”, 0.1% solution for intravenous administration, 
5 ml, ampouled, manufactured by ”Isis Pharm GmbH” 
(Germany), series 05x 11178, exp. date 12.2017).
The highest clinical dose (HTD) administered in all the 
experiments and for all the types of laboratory animals 
did not exceed 5% of the LD50 value determined for mice 
for the tested administration route.
The calculation of the dose for dogs and rats was car-
ried out taking into account the rules of interspecific re-es-
timation from the dose of mice (Freireich et al. 1966). To 
determine the accumulated effective dose (AED) in ex-
periments in dogs, the infusion of the substances was per-
formed, but no more than before reaching HTD.
Experimental methods
The antiarrhythmic effect of the compounds under the 
conditions of reperfusion arrhythmia was studied in the 
experiments on rats on the models of transient ische-
mic attacks and reperfusion arrhythmias and reperfusion 
heart rhythm disturbances induced by ischemic heart sti-
mulation of rats, as well as in experiments when reper-
Figure 1. Chemical structures of 2-aminoaethanesulfonic acid compounds
fusion was reproduced 120 min after ischemia onset in 
dogs (Milan and MacRae 2005). To determine the size 
of heart ischemia and necrosis, the differential indicator 
method by Sernov and Gatzura (1989) was used, in our 
modification allowing reperfusion of the myocardium 120 
minutes after an acute ischemia onset. The intensity of 
lipid peroxidation processes and the antiradical potency 
of myocardial tissue was studied by chemiluminescent 
method using Emilit EL photometer (USA). The impact 
of the tested compounds on some metabolic parameters 
was determined by the concentration levels of oxygen, 
carbon dioxide, pH, the capacity of carbonate buffer in 
dogs’ coronary venous sinus blood by using EasyBlood-
Gaz analyzer (USA). The hemodynamic effects of LKhT-
317 and LBK-527 were studied in a non-invasive manner 
(two-channel CODA system, Kent Scientific, USA). The 
contractile activity of the left ventricle during the ische-
mia/reperfusion period was determined by recording the 
dP/dtmax rate by means of a blood pressure (BP) transducer 
(“Ugo Basile”, Italy) and a recorder by the same manu-
facturer. The effect of the compounds on the volume of 
outflowing perfusate and an isolated heart survival time 
was studied in the hypoxic/reoxygenated rats’ hearts by 
Langendorff method (Takeo et al. 1988). 
The statistic significance of the obtained results was 
estimated with modern statistics methods using licensed 
PC interface “BioStat”, SPSS and PC iMac Retina (USA).
Results and discussion
The efficacy of the substances on the model of late re-
perfusion arrhythmia was studied in dogs under the cir-
cumstances of coronary artery recanalization performed 
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2 hours after the development of acute ischemia. The 
methodical technique allowed determining AEDs of 
the tested substances, reaching which either completely 
suppressed arrhythmia, or reduced the ectopic activity 
by more than 50%. It was determined that the AED of 
LKhT-317 was greater than that of lidocaine, but lower 
than that of amiodarone (Figure 2). Unlike amiodarone, 
LKhT-317 brought about complete antiarrhythmic effect, 
but unlike lidocaine hydrochloride, the duration of the 
antiarrhythmic action of the substance was significantly 
higher. The magnesium-containing derivative of 2-ami-
noethanesulfonic acid (LBK-527) had the lowest antiarr-
hythmic effect among all the pharmacological substances 
studied: no cases were recorded of complete suppression 
of ectopic activity. However, it should be stressed that the 
achievement of a partial antiarrhythmic effect in all ani-
mals was observed with the administration of a total dose 
of the substance not exceeding 50% of HTD. It is also 
noteworthy that the duration of the substance action was 
significantly higher than that of lidocaine, but inferior to 
that of amiodarone.
The model of early reperfusion arrhythmia in rats made 
it possible to study the prophylactic effectiveness of ad-
ministering the tested compounds intravenously to restore 
coronary blood flow after a relatively short period of acute 
ischemia - 7 minutes (Figure 2). So, in this model, the opti-
mal administered dose of LKhT-317 can be considered 4.2 
mg/kg, at which the substance showed a full antiarrhyth-
mic and antifibrillatory effects. As for the peculiarities of 
pharmacodynamics of LBK-527 on the model described, 
it should be emphasized that, like on the late reperfusion 
model, the antiarrhythmic activity of the substance was 
less pronounced than that of LKhT-317. At a dose of 50% 
of HTD, the compound showed no activity at all. An in-
crease in the dose to reach HTD resulted in a milder effect 
in comparison with that of the reference medications.
Unlike the aforementioned models of reperfusion 
rhythm disorders, the model of electro-stimulated ar-
rhythmia is based on a fundamentally different approach. 
Firstly, the duration of the ischemia period is 30-35 min, 
the time during which the irreversible processes of cell 
death of the most ischemia-affected myocardium zones 
can start in animals. Secondly, rhythm disturbances are 
generated actively by electrical stimulation, thus creating 
a more aggressive pathological environment, allowing a 
more objective assessment of the antifibrillatory efficien-
cy of the potential drugs.
Pharmacologucal effect of the tested compounds on this 
model is characterized, first, by LKhT-317 having antifibril-
latory action, which is comparable with that of amiodarone, 
and, secondly, in comparison with lidocaine the compound 
action duration increases up to 30-35 min of observation 
(Figure 2). Magnesium-containing 2-aminoethanesulfon-
ic acid derivative (LBK-527) also has antifibrillatory ac-
tion on the model of electrical stimulation of myocardium 
during reperfusion, however, by the preventing action in-
tensity, the compound is significantly inferior to the deriv-
ative of LKhT-317 and the reference drug – amiodarone. 
Both compounds are more active than lidocaine.
The most favorable scenario for development of oc-
clusion-reperfusion syndrome is ischemic precondition-
ing, which allows the cellular structures of the ischemic 
myocardium to rearrange for an optimal mode of energy 
production and oxygen consumption (Murphy and Steen-
bergen 2008).
Using a differential indicator method for determining 
the size of ischemia and necrosis zones rats’ hearts with 
reperfusion syndrome (Table 1), it was determined that 
intravenous administration of LKhT-317 is accompanied 
by a reduced volume of irreversible damage to the heart 
muscle, comparable to that when administering proprano-
lol and amiodarone. At the same time, LKhT-317 did not 
reduce the size of the ischemic zone. The efficacy of the 
second tested compound – a magnesium-containing de-
rivative of 2-aminoethanesulfonic acid LBK-527 – was 
the smallest among all medications investigated. Reduc-
tion in the size of the necrosis zone caused by the com-
pound was statistically significant when compared with 
that in the control, but it was smaller in comparison with 
the other substances.
Thus, magnesium and phenylacetamide-containing salts 
of 2-aminoethane-sulfonic acid have a cardioprotective ef-
fect in myocardium reperfusion injury, which manifests 
itself in limiting the volumes of irreversible myocardial 
damage. Consequently, it can be assumed that substances 
can transfer the hearts of animals to a state of ischemic 
Figure 2. Comparison of the antiarrhythmic action of com-
pounds by duration and/or rate on different reperfusion-induced 
arrhythmia animal models
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preconditioning, which is the most favorable mechanism 
of adapting to ischemic and reperfusion syndrome.
Assessment of the state of metabolic processes in the 
myocardium under reperfusion conditions is an important 
component of studying the role of potential drugs in the 
prevention and correction of heart reperfusion injury. Re-
oxygenation of tissues in ischemia entails the activation 
of oxygen-dependent enzyme systems with sometimes 
dramatic consequences for cells and tissue in general. In 
experiments on dogs in which after 30 min of occlusion, 
reperfusion injury of the heart was reproduced for 15 min, 
partial oxygen and carbon dioxide pressure and saturation, 
pH, and the capacity of the carbonate buffer system were 
studied. The compounds under study effectively prevent-
ed the pathological shifts of the homeostatic indices of 
blood flowing from the myocardium damaged zone: there 
was correction of ischemic acidosis and of gas pressure in 
blood, indicating the formation of an optimal mode of ox-
ygen consumption by the myocardium. It should be noted 
that both compounds, but LKhT-317 to a greater extent, 
were active in preventing the negative consequences of 
reperfusion, rather than of ischemic damage.
Numerous studies conducted recently in the world have 
shown that the use of protocols that inhibit the develop-
ment of lipid peroxidation and the active oxygen interme-
diates inducing its release leads to a significant weakening 
of the damaging effect of reperfusion on cardiac tissue. 
When  studying intravenous administration of magnesium 
salt of 2-aminoethanesulfonic acid (LBK-527) at HTD, 
a protective effect on the processes of lipid peroxidation 
induced by reperfusion was revealed (Table 2). The in-
tensity of the lipid peroxidation decreased whereas an-
tioxidant activity increased, but its values  did not reach 
the level of peroxidation activity at the affected area of 
the myocardium. In contrast, administration of LKhT-317 
as a heart-protector along with a decrease in the level of 
lipid peroxidative process proportionally intensified the 
antioxidant activity of heart tissue, repeating the pharma-
cological effect of reference medication  verapamil.
Possibly the established activity of LKhT-317 may be 
related to the proven ability of dimethylphenylacetamide 
and some of its derivatives to inhibit lipid peroxydation 
processes and to activate protective reactions in heart of 
animals under experimental conditions (Yakya et al. 2018).
Untimately, ischemic and reperfusion heart injury leads 
to the death of part of parenchymal cells of the organ, 
violations of the contractile function and electrophysio-
logical changes that result in electrical instability of the 





Necrosis share of total weight 
of the myocardium (%)
Ischemia share of total weight 
of the myocardium (%)
Ratio of the ischemic zone size 
to the necrosis zone size, %
Control no. 1 – 6 45.4±2.0 22.2±1.6 49.6±4.4
Control no. 2 – 6 36.8±1.8а 20.4±2.1 56.5±2.0
Amiodarone 28.5 6 31.5±2.2* 20.2±1.4 64.1±2.3*
Propranolol 0.8 6 28.1±1.1* 21.2±1.2 75.4±2.6*
LBK-527 15.0 6 30.3±1.2* 20.7±1.6 68.3±1.4*
LKhT-317 4.2 6 31.7±1.8* 20.8±1.8 65.6±1.8*
Note: * in comparison with control no. 2, differences are statistically significant at р<0,05; а in comparison with control no. 1, dif-
ferences are statistically significant at р<0,05 (one-dimension dispersion analysis; Newman-Keuls criterion)
Table 2. General antyperoxidant activity and intensity of free-radical lipoperoxidation in rats’ myocardium after reperfusion and iv 
administration of 2-aminoaethanesulfonic acid compounds  (M±SD)
Attack intensity,  
imp/sec Drug, dose (mg/kg)
Measuring point
LA LV RZ LV IZ
Lipid peroxidation
Control no.1 4.5±0.6 9.7±0,5 8.9±0.7
Control no.2 5.1±1.2 12.2±1.8 67.4±4.7а
LBK-527, 15.0 4.8±0.8 11.3±1.1 42.1±2.4*
LKhT-317, 4.2 5.0±0.6 10.9±0.9 38.6±4.2*
Verapamil, 1.7 4.9±1.2 12.0±1.3 32.5±3.1*
Antioxidant activity
Control no.1 4.8±0.5 10.1±1.0 10.2±0.8
Control no.2 5.3±0.9 6.7±0.7 23.4±3.6а
LBK-527, 15.0 4.5±0.8 7.8±1.4 32.6±2.7*
LKhT-317, 4.2 5.4±1.2 8.6±1.5 38.7±3.8f
Verapamil, 1.7 4.7±0.7 8.9±2.5 36.4±2.5 f
Note: RZ LV – remote zone of left ventricle; IZ LV – intact zone of left ventricle; LA – left atrium. * in comparison with control 
no. 1, differences are statistically significant at р<0.05; а in comparison with control no. 1, differences are statistically significant 
at р<0,05;f in comparison with control no. 1 and control no. 2, differences are statistically significant at р<0,05 (One-dimension 
dispersion analysis; Newman-Keuls criterion)
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myocardium, the dysfunction of its rhythmic activity, and 
the generation of cardiac rhythm disturbances. Therefore, 
at the final stage of the study, the effect of prophylactic 
administration of 2-aminoethanesulfonic acid compounds 
on the hemodynamics of the animals with experimen-
tal reperfusion syndrome and the bioelectrical activity 
of an isolated heart was evaluated. LKhT-317 showed 
most significant cardioprotective properties prevent-
ing hemodynamic disorders. Its preventive intravenous 
administration at a dose of 4.2 mg/kg did not affect the 
ischemic period of the experiment. However, the severi-
ty of the reperfusive hemodynamic shifts was obviously 
lower than that in the control: the compound prevented 
a negative inotropic reperfusion effect, as well as a criti-
cal stagnation of blood pressure. At the same time, both 
compounds favorably influenced the hemodynamic con-
sequences of reperfusion syndrome, which showed in the 
prevention of contractility and BP functions. The results 
obtained can be explained by the ability of compounds to 
prevent excessive activation of lipid peroxydation, opti-
mization of metabolic processes in the myocardium, and 
antiarrhythmic properties of LBK-527 and LKhT-317.
In the experiments in Langendorff isolated rat’s heart, 
global hypoxia/reoxygenation was reproduced (Figure 3). 
During 15 minutes of global cardiac hypoxia, the progres-
sive extinction of the bioelectric and pumping functions 
of the organ was observed, which showed in a decrease 
in heart rate on average from 40 to 27 beats per min. and 
a decrease in the rate of perfusate outflow by 30% of the 
initial level.
Reoxygenation performed on the 15th minute of the ex-
periment led to a short-term and incomplete recovery of 
both the rhythm frequency and the volume indices of the 
intracardiac dynamics of the perfusion solution, but by 
the final phase of observation, the bioelectrical activity of 
the isolated heart faded.
The magnesium-containing salt of 2-aminoethanesul-
fonic acid (LBK-527) at a concentration of 10-4 M had 
practically no effect on the performance of the isolated 
heart during the hypoxia period, but it stimulated a more 
efficient recovery of the lost functions of the organ during 
the reoxygenation, which showed in a significant, in com-
parison with the control group, increase in heart rate, 
measured at 30 and 45 minutes of the experiment and in 
volume indices of intracardiac hemodynamics. Even more 
contrasting results were obtained against the background 
of perfusion of the isolated heart with the Krebs-Hanseleit 
solution containing LKhT-317 in the same concentration: 
the heart rate, the rate of perfusate outflow were restored, 
and the volume of the outflowing perfusate was main-
tained at a high level. The results obtained indicate a high 
protective function of the compounds under conditions of 
hypoxia/reoxygenation of isolated heart. 
Thus, the experimental study analysis showed that 
2-aminoethanesulfonic acid compounds have cardiopro-
tective activity in reperfusion syndrome. LKhT-317 and 
LBK-527 at therapeutic doses effectively prevent the for-
mation of reperfusion rhythm disorders after 7-, 30- and 
120-minute of acute ischaemia. Preventive administration 
of the substances limits the activation of lipid peroxida-
tion processes in the myocardium, optimizes oxygen con-
sumption during reperfusion, which reduces the size of 
the infarction zone by 20-25% when compared with those 
in the animals in the control group. Modulation of meta-
bolic homeostasis leads to weakening the manifestations 
of electrical instability of the myocardium, as well as 
maintaining its contractility at a level sufficient to main-
tain hemodynamic stability.
Conclusions
According to the obtained data, the following conclusions 
were made: 
1. Magnesium-containing (LBK-527) and phenylac-
etamide-containing (LKhT-317) 2-aminoethanesulfon-
ic acid compounds effectively prevent the generation of 
cardiac arrhythmias caused by myocardial reperfusion of 
animals’ heart after 7, 30 and 120 minutes of ischemia.
2. Prophylactic intravenous administration of LKhT-
317 and LBK-527 at higher therapeutic doses limit the 
size of rats’ heart necrosis zone after occlusion-reperfu-
sion syndrome develops and are as effective as the refer-
ence medications amiodarone and propranolol.
3. The tested compounds prevent reperfusion-induced 
excessive activation of free-radical processes in rat’s 
myocardium; activate the antiradical activity of the heart 
tissues. Their intravenous injection before coronary ar-
tery occlusion is followed by optimization of oxygen and 
carbon dioxide partial pressure in coronary venous sinus 
blood of dogs, acidosis correction in response to the resto-
ration of blood flow through the coronary arteries.
4. Cardioprotective effect of LBK-527 and LKhT-317 
in experimental reperfusion syndrome shows in preserv-
ing the myocardium contractile function, maintaining BP 
and stabilizing heart chronotropic function.
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Figure 3. Dynamics of perfusate outflow rate and and of total volume of outflowing perfusate over 15 minutes of experiment (Vtotal) 
when administering LBK-527 and LKhT-317 Note: * in comparison with control, differences are statistically significant at р<0,05 
(One-dimension dispersion analysis; Newman-Keuls criterion) (M±SD)
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